GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting


SOUTH SAN FRANCISCO, Calif., /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company's industry-leading Surge technology against 17 unique immuno-oncology targets. The conference takes place November 7-11, 2018 at the Walter E. Washington Convention Center in Washington, D.C.

Logo (PRNewsfoto/GigaGen Inc.)

"Our research presented at SITC continues to demonstrate Surge's ability to identify thousands of full-length human antibodies directed against a wide array of diverse immuno-oncology targets, which may provide benefit to patients that don't respond to currently available checkpoint inhibitors," said David Johnson, Ph.D., Chief Executive Officer. "We are testing efficacy of the most promising antibodies and plan to advance candidates with best-in-class potential into clinical studies."

Details of GigaGen's SITC 2018 presentation are as follows:

Poster Number: P646
Title: "Discovery and characterization of therapeutic human monoclonal antibodies against 17 immuno-oncology targets using microfluidics and molecular genomics"
Date: Saturday, November 10, 2018
Times: 12:20 - 1:50 p.m.; 7:00 - 8:30 p.m.
Location: Hall E, Walter E. Washington Convention Center, Washington D.C.

About GigaGen
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit



Cision View original content to download multimedia:

SOURCE GigaGen Inc.


Back to news